Kintara Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement
prnewswire.com
news
2022-06-03 13:00:00

SAN DIEGO, June 3, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc.Â (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that the Company received written notification from the Listing Qualification Department of The Nasdaq Stock Market LLC ("Nasdaq") granting the Company's request for a 180-day extension to regain compliance with Nasdaq's minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).
